Hasten Biopharmaceutical Co., Ltd. (Hasten) and China Resources Pharmaceutical Commercial Group (Shanghai) Co., Ltd. reached a strategic cooperation at the 6th CIIE on November 7th of 2023. Mr. Summer Xia, CEO of Hasten, Mr. Kevin Gu, SVP and Head of MAC & Global Business of Hasten, and Mr. Guo Junyu, Deputy General Manager of China Resources Pharmaceutical Commercial Group (China Resources), were present at the event and witnessed the conclusion of the strategic cooperation.

This cooperation is based on the principles of "integrity and collaboration, complementary advantages, shared responsibility and shared resources", and jointly establish a long-term and stable strategic partnership. According to the cooperation agreement, China Resources（Shanghai）will act as the exclusive import distributor of one of Hasten's strategic products - Stilamin® in Chinese Mainland and support Hasten to benefit more patients with high-quality drugs via its strength in logistics and innovative pharmaceutical supply chain solutions, which will jointly create greater social and health value for people in China.

Summer Xia，CEO of Hasten，said: “Taking the advantage of CIIE, Hasten joins hands with our key strategic partner, China Resources here. We are very pleased and look forward to joining forces with China Resources（Shanghai） to bring more quality products and solutions to Chinese patients, improve access to medicines, and contribute to the realization of the ‘Healthy China 2030’strategy.”